NovaSeq 6000 Sequencing System is by far our most powerful instrument, designed to adapt to your needs.
Kits & Reagents
P1 reagents are now available for NextSeq 1000/NextSeq 2000 Systems, offering added flexibility to meet your project's needs
Selection & Planning Tools
A high-performing, fast, and integrated workflow for sensitive applications such as human whole-genome sequencing
Software & Informatics Products
DRAGEN v3.9 release now available with multi-cloud support, accuracy improvements and more
Fast, high-quality, sample-to-data services such as RNA and whole-genome sequencing
Improved Q30 score, support for UMIs, extended shelf life, and support for Illumina DNA PCR-Free Library Prep
See what is possible through the latest advances in high-throughput sequencing technology
Illumina and the San Diego Zoo Wildlife Alliance try to preserve the species with the help of genomic data
All Investor Information
Upgrade your MiSeqDx instrument from Windows 7 to Windows 10
All Support Tools
Product Support Services
Multiomics methods can better connect genotype to phenotype
Cancer Research Products
Microbial Genomics Research
Learn about methods for SARS-CoV-2 surveillance, including requirements, workflow, and analysis
Microbial Genomics Products
Array-based SNP genotyping platforms have low genotype error rates compared to genotyping-by-sequencing
Explore the advantages of NGS for analysis of gene expression, gene regulation, and methylation
Complex Disease Research Products
Prof. Dr. Bernd Eiben discusses his experience with VeriSeq NIPT Solution v2
Reproductive Health Products
Illumina supports the release of a landmark consensus on whole-genome sequencing in the diagnosis of genetic diseases in newborns
Genetic Health Products
Fueling the future of precision medicine and targeted therapies with NGS-based companion diagnostics (Dx).
Illumina provides an innovative portfolio of NGS systems, products, and services for many phases of the drug development pipeline.
This DrugDev Consortium-designed genotyping array covers ADME genes and the druggable genome to support drug target selection and validation.